Virus-like particles as universal influenza vaccines

Current influenza vaccines are primarily targeted to induce immunity to the influenza virus strain-specific hemagglutinin antigen and are not effective in controlling outbreaks of new pandemic viruses. An approach for developing universal vaccines is to present highly conserved antigenic epitopes in an immunogenic conformation such as virus-like particles (VLPs) together with an adjuvant to enhance the vaccine immunogenicity. In this review, the authors focus on conserved antigenic targets and molecular adjuvants that were presented in VLPs. Conserved antigenic targets that include the hemagglutinin stalk domain, the external domain of influenza M2 and neuraminidase are discussed in addition to molecular adjuvants that are engineered to be incorporated into VLPs in a membrane-anchored form.

[1]  John Steel,et al.  Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain , 2010, mBio.

[2]  A. Kendal,et al.  Antibody response to the M2 protein of influenza A virus expressed in insect cells. , 1993, The Journal of general virology.

[3]  David J Stevens,et al.  Structure of the Hemagglutinin Precursor Cleavage Site, a Determinant of Influenza Pathogenicity and the Origin of the Labile Conformation , 1998, Cell.

[4]  T M Moran,et al.  Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[5]  F. Marincola,et al.  Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation , 2005, Journal of Translational Medicine.

[6]  E. D. Kilbourne,et al.  Protective Effects of Specific Immunity to Viral Neuraminidase on Influenza Virus Infection of Mice , 1968, Journal of virology.

[7]  R. Compans,et al.  Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. , 2003, Virology.

[8]  C. Schroeder,et al.  Different modes of inhibition by adamantane amine derivatives and natural polyamines of the functionally reconstituted influenza virus M2 proton channel protein. , 1997, The Journal of general virology.

[9]  Wentao Gao,et al.  Protection of Mice and Poultry from Lethal H5N1 Avian Influenza Virus through Adenovirus-Based Immunization , 2006, Journal of Virology.

[10]  R. Lamb,et al.  Permeation and Activation of the M2 Ion Channel of Influenza A Virus* , 2000, The Journal of Biological Chemistry.

[11]  F. Kostolanský,et al.  Changes in the influenza virus haemagglutinin at acid pH detected by monoclonal antibodies to glycopolypeptides HA 1 and HA 2 , 2005, Archives of Virology.

[12]  S. Zhang,et al.  Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV. , 2010, Vaccine.

[13]  R. Compans,et al.  Induction of Heterosubtypic Immunity to Influenza Virus by Intranasal Immunization , 2007, Journal of Virology.

[14]  Mark R. Soboleski,et al.  Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. , 2009, Vaccine.

[15]  P. Roy,et al.  Virus‑like particles as a vaccine delivery system: Myths and facts , 2008, Human vaccines.

[16]  D. Suarez,et al.  Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. , 2007, Vaccine.

[17]  R. Compans,et al.  Incorporation of Glycosylphosphatidylinositol-Anchored Granulocyte- MacrophageColony-Stimulating Factor or CD40 Ligand Enhances Immunogenicity of Chimeric Simian Immunodeficiency Virus-Like Particles , 2006, Journal of Virology.

[18]  R. Lamb,et al.  Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions , 1988, Journal of virology.

[19]  Larry R. Smith,et al.  Cross-Reactive Neuraminidase Antibodies Afford Partial Protection against H5N1 in Mice and Are Present in Unexposed Humans , 2007, PLoS medicine.

[20]  R. Webster,et al.  Changes in the antigenicity of the hemagglutinin molecule of H3 influenza virus at acidic pH. , 1983, Virology.

[21]  K. Schwarz,et al.  Efficient induction of mucosal and systemic immune responses by virus‐like particles administered intranasally: implications for vaccine design , 2008, European journal of immunology.

[22]  K. Schwarz,et al.  Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects , 2004, The Journal of Immunology.

[23]  T. Kurata,et al.  Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. , 2000, Vaccine.

[24]  W. Fiers,et al.  Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection , 2011, The Journal of Immunology.

[25]  P. Ricciardi-Castagnoli,et al.  Dendritic cells process exogenous viral proteins and virus‐like particles for class I presentation to CD8+ cytotoxic T lymphocytes , 1996, European journal of immunology.

[26]  R. Compans,et al.  Effect of Antibody to Neuraminidase on the Maturation and Hemagglutinating Activity of an Influenza A2 Virus , 1969, Journal of virology.

[27]  R. Compans,et al.  Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. , 2012, Virology.

[28]  H. Klenk,et al.  Neuraminidase Is Important for the Initiation of Influenza Virus Infection in Human Airway Epithelium , 2004, Journal of Virology.

[29]  Ying-hua Chen,et al.  Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. , 2005, Microbes and infection.

[30]  Yukiko Muramoto,et al.  The Cytoplasmic Tail of the Influenza A Virus M2 Protein Plays a Role in Viral Assembly , 2006, Journal of Virology.

[31]  Andrew Pekosz,et al.  The Influenza A Virus M2 Cytoplasmic Tail Is Required for Infectious Virus Production and Efficient Genome Packaging , 2005, Journal of Virology.

[32]  Suh-Chin Wu,et al.  Fabrication of influenza virus-like particles using M2 fusion proteins for imaging single viruses and designing vaccines. , 2011, Vaccine.

[33]  W. Fiers,et al.  An antibody which binds to the membrane-proximal end of influenza virus haemagglutinin (H3 subtype) inhibits the low-pH-induced conformational change and cell-cell fusion but does not neutralize virus. , 1998, The Journal of general virology.

[34]  R. Hai,et al.  Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins , 2010, PLoS pathogens.

[35]  C. Davis,et al.  Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. , 2010, Virology.

[36]  Q. Yao,et al.  Th Cell-Independent Immune Responses to Chimeric Hemagglutinin/Simian Human Immunodeficiency Virus-Like Particles Vaccine1 , 2004, The Journal of Immunology.

[37]  R. Lamb,et al.  Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. K. Evans,et al.  Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. , 2008, Vaccine.

[39]  R. Zinkernagel,et al.  The influence of antigen organization on B cell responsiveness. , 1993, Science.

[40]  Emily P. Wen,et al.  Universal Influenza B Vaccine Based on the Maturational Cleavage Site of the Hemagglutinin Precursor , 2005, Journal of Virology.

[41]  W. Fitch,et al.  Predicting the evolution of human influenza A. , 1999, Science.

[42]  M. Krugliak,et al.  How do aminoadamantanes block the influenza M2 channel, and how does resistance develop? , 2011, Journal of the American Chemical Society.

[43]  E. D. Kilbourne,et al.  Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. , 1998, Vaccine.

[44]  R. Belshe.  Current status of live attenuated influenza virus vaccine in the US. , 2004, Virus research.

[45]  T. Tumpey,et al.  Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1 , 2007, Emerging infectious diseases.

[46]  E. D. Kilbourne,et al.  Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection , 1989, Journal of virology.

[47]  T. Mettenleiter,et al.  Protection of chickens against H5N1 highly pathogenic avian influenza virus infection by live vaccination with infectious laryngotracheitis virus recombinants expressing H5 hemagglutinin and N1 neuraminidase. , 2009, Vaccine.

[48]  A. Jegerlehner,et al.  Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity , 2004, The Journal of Immunology.

[49]  R. Varadarajan,et al.  Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge , 2010, Proceedings of the National Academy of Sciences.

[50]  T. Tumpey,et al.  Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. , 2007, Vaccine.

[51]  Jeffrey B Ulmer,et al.  Targeting the innate immune response with improved vaccine adjuvants , 2005, Nature Medicine.

[52]  C. Leclerc,et al.  CD8α2 CD11b+ Dendritic Cells Present Exogenous Virus-like Particles to CD8+ T Cells and Subsequently Express CD8α and CD205 Molecules , 2002, The Journal of experimental medicine.

[53]  R. Lamb,et al.  The M1 and M2 proteins of influenza A virus are important determinants in filamentous particle formation. , 1998, Virology.

[54]  W. Fiers,et al.  A "universal" human influenza A vaccine. , 2004, Virus research.

[55]  R. Webster,et al.  Protection against lethal influenza with neuraminidase. , 1988, Virology.

[56]  J. Shiver,et al.  Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. , 2006, Journal of pharmaceutical sciences.

[57]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[58]  Rolf M. Zinkernagel,et al.  Immunology Taught by Viruses , 1996, Science.

[59]  R. Compans,et al.  Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus , 2010, Proceedings of the National Academy of Sciences.

[60]  A. Jegerlehner,et al.  Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles1 , 2002, The Journal of Immunology.

[61]  R. Lamb,et al.  Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly. , 1995, Virology.

[62]  R. Compans,et al.  Incorporation of Membrane-Anchored Flagellin into Influenza Virus-Like Particles Enhances the Breadth of Immune Responses , 2008, Journal of Virology.

[63]  R. Lamb,et al.  Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface , 1985, Cell.

[64]  J. Pandey.  Comment on “Flagellin as an Adjuvant: Cellular Mechanisms and Potential” , 2011, The Journal of Immunology.

[65]  A. Iwasaki,et al.  Induction of antiviral immunity requires Toll-like receptor signaling in both stromal and dendritic cell compartments. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Vikas Nanda,et al.  Structural basis for the function and inhibition of an influenza virus proton channel , 2008, Nature.

[67]  T. Ross,et al.  Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. , 2007, Vaccine.

[68]  M. Osterholm,et al.  Preparing for the next pandemic. , 2005, The New England journal of medicine.

[69]  E. D. Kilbourne,et al.  Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition , 1993, Journal of virology.

[70]  F. Kostolanský,et al.  Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. , 2011, Acta virologica.

[71]  Shuhan Sun,et al.  Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection. , 2006, DNA and cell biology.

[72]  J. Kwang,et al.  Monoclonal Antibodies against the Fusion Peptide of Hemagglutinin Protect Mice from Lethal Influenza A Virus H5N1 Infection , 2008, Journal of Virology.

[73]  E. Rajnavölgyi,et al.  A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection. , 1998, Immunology letters.

[74]  Lawrence H. Pinto,et al.  Influenza virus M2 protein has ion channel activity , 1992, Cell.

[75]  B. Johansson.  Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. , 1999, Vaccine.

[76]  W. Fiers,et al.  Improved design and intranasal delivery of an M2e-based human influenza A vaccine. , 2006, Vaccine.

[77]  G L Ada,et al.  Options for the control of influenza III. Cairns, North Queensland, Australia (4-9 May 1996). , 1997, Vaccine.

[78]  D. Ekiert,et al.  Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes , 2010, Proceedings of the National Academy of Sciences.

[79]  W. Fiers,et al.  An Influenza A Vaccine Based on Tetrameric Ectodomain of Matrix Protein 2* , 2008, Journal of Biological Chemistry.

[80]  Mark A. Miller,et al.  Preliminary Estimates of Mortality and Years of Life Lost Associated with the 2009 A/H1N1 Pandemic in the US and Comparison with Past Influenza Seasons , 2010, PLoS currents.

[81]  T. Tumpey,et al.  Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. , 2006, Vaccine.

[82]  J. Shiver,et al.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. , 2004, Vaccine.

[83]  R. Compans,et al.  Human immunodeficiency virus-like particles activate multiple types of immune cells. , 2007, Virology.

[84]  R. Webster,et al.  Reactions of antibodies with surface antigens of influenza virus. , 1968, The Journal of general virology.

[85]  T. Tumpey,et al.  Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle , 2008, PloS one.

[86]  Larry R. Smith,et al.  Vaxfectin™-Formulated Influenza DNA Vaccines Encoding NP and M2 Viral Proteins Protect Mice against Lethal Viral Challenge , 2007, Human vaccines.

[87]  G. Van Domselaar,et al.  Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. , 2010, Biochemical and biophysical research communications.

[88]  R. Elliott,et al.  Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[89]  R. Compans,et al.  Host responses from innate to adaptive immunity after vaccination: Molecular and cellular events , 2009, Molecules and cells.

[90]  R. Compans,et al.  Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. , 2003, Virology.

[91]  G. Domselaar,et al.  A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide , 2010, Nature Protocols.

[92]  J. Chou,et al.  Structure and mechanism of the M2 proton channel of influenza A virus , 2008, Nature.

[93]  J. Skehel,et al.  The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. , 1987, Annual review of biochemistry.

[94]  Bin Zhou,et al.  In vitro stimulation of human influenza-specific CD8+ T cells by dendritic cells pulsed with an influenza virus-like particle (VLP) vaccine. , 2010, Vaccine.

[95]  J. Young,et al.  Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. , 1983, Virology.

[96]  J. Skehel,et al.  The molecular basis of the specific anti‐influenza action of amantadine. , 1985, The EMBO journal.

[97]  G. Air,et al.  Amino acid sequence changes in the haemagglutinin of A/Hong Kong (H3N2) influenza virus during the period 1968–77 , 1980, Nature.

[98]  F. Buonaguro,et al.  Baculovirus-Derived Human Immunodeficiency Virus Type 1 Virus-Like Particles Activate Dendritic Cells and Induce Ex Vivo T-Cell Responses , 2006, Journal of Virology.

[99]  Guowei Wei,et al.  Potent Neutralization of Influenza A Virus by a Single-Domain Antibody Blocking M2 Ion Channel Protein , 2011, PloS one.

[100]  Boguslaw Stec,et al.  Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses , 2009, Nature Structural &Molecular Biology.

[101]  T. Ross,et al.  Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. , 2007, Virology.

[102]  R. Compans,et al.  Enhanced Mucosal Immune Responses to HIV Virus-Like Particles Containing a Membrane-Anchored Adjuvant , 2011, mBio.

[103]  H. Hammad,et al.  Cutting Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome , 2008, The Journal of Immunology.

[104]  B. Johansson,et al.  Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. , 2005, Virology.

[105]  C. Leclerc,et al.  In Vivo, Dendritic Cells Can Cross-Present Virus-Like Particles Using an Endosome-to-Cytosol Pathway 1 , 2003, The Journal of Immunology.

[106]  R. Compans,et al.  Virus-Like Particle Vaccine Induces Protective Immunity against Homologous and Heterologous Strains of Influenza Virus , 2007, Journal of Virology.

[107]  R. Webster,et al.  Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies , 1981, Nature.

[108]  R. Compans,et al.  Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. , 1976, The Journal of general virology.

[109]  R. Lamb,et al.  Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice , 1990, Journal of virology.

[110]  Gira Bhabha,et al.  Antibody Recognition of a Highly Conserved Influenza Virus Epitope , 2009, Science.

[111]  Bali Pulendran,et al.  Translating Innate Immunity into Immunological Memory: Implications for Vaccine Development , 2006, Cell.

[112]  H. Hoogsteden,et al.  Lung dendritic cells and host immunity to infection. , 2001, The European respiratory journal.

[113]  Jianjun Chen,et al.  Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. , 2005, Vaccine.

[114]  B. Pulendran,et al.  The science of adjuvants , 2007, Expert review of vaccines.

[115]  I. Wilson,et al.  Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution , 1981, Nature.

[116]  C. Davis,et al.  Induction of Long-Term Protective Immune Responses by Influenza H5N1 Virus-Like Particles , 2009, PloS one.

[117]  Huálín Wáng,et al.  Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in BALB/c mice. , 2006, Biochemical and biophysical research communications.

[118]  E. D. Kilbourne,et al.  Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. , 1996, Virology.

[119]  Jonathan Dushoff,et al.  Codon bias and frequency-dependent selection on the hemagglutinin epitopes of influenza A virus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[120]  R. Contreras,et al.  Protection of mice against a lethal influenza challenge by immunization with yeast-derived recombinant influenza neuraminidase. , 1997, European journal of biochemistry.

[121]  Ying-hua Chen,et al.  Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine. , 2009, Vaccine.

[122]  G. Tian,et al.  Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes , 2003, Avian pathology : journal of the W.V.P.A.

[123]  Shiyun Chen,et al.  Increasing M2 epitope density enhances systemic and mucosal immune responses to influenza A virus , 2009, Biotechnology Letters.

[124]  M. Eichelberger,et al.  Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses , 2011, Proceedings of the National Academy of Sciences.

[125]  Larry R. Smith,et al.  Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. , 2008, The Journal of infectious diseases.

[126]  A. Hay,et al.  Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells. , 1996, The Journal of physiology.

[127]  Z. Zhou,et al.  Influenza virus morphogenesis and budding , 2009, Virus Research.

[128]  David N. Taylor,et al.  Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. , 2011, Vaccine.

[129]  J. Bates,et al.  Flagellin as an Adjuvant: Cellular Mechanisms and Potential , 2010, The Journal of Immunology.

[130]  J. Shiver,et al.  Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. , 2009, Vaccine.

[131]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[132]  R. Compans,et al.  Immunogenicity of low-pH treated whole viral influenza vaccine. , 2011, Virology.

[133]  W. C. Gamble,et al.  Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. , 1995, Vaccine.

[134]  R. Compans,et al.  Intranasal Immunization with Influenza VLPs Incorporating Membrane-Anchored Flagellin Induces Strong Heterosubtypic Protection , 2010, PloS one.

[135]  E. D. Kilbourne,et al.  Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[136]  Larry R. Smith,et al.  Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. , 2010, Vaccine.

[137]  R. Lamb,et al.  Expression of the influenza A virus M2 protein is restricted to apical surfaces of polarized epithelial cells , 1992, Journal of virology.

[138]  J. Treanor,et al.  Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). , 2011, Vaccine.

[139]  B. Johansson,et al.  Changing perspective on immunization against influenza. , 2007, Vaccine.

[140]  P. Heinen,et al.  Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. , 2002, The Journal of general virology.

[141]  W. Fiers,et al.  Recombinant neuraminidase vaccine protects against lethal influenza. , 1996, Vaccine.

[142]  W. Fiers,et al.  Universal influenza A vaccine: optimization of M2-based constructs. , 2005, Virology.

[143]  R. Zinkernagel,et al.  Cutting Edge Commentary: Immune Responses in the Absence of Costimulation: Viruses Know the Trick , 1998, The Journal of Immunology.

[144]  G. Air,et al.  Antigenic drift in type A influenza virus: peptide mapping and antigenic analysis of A/PR/8/34 (HON1) variants selected with monoclonal antibodies. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[145]  B. Haynes,et al.  Incorporation of High Levels of Chimeric Human Immunodeficiency Virus Envelope Glycoproteins into Virus-Like Particles , 2007, Journal of Virology.

[146]  Min-Chul Kim,et al.  Influenza Virus-Like Particles Containing M2 Induce Broadly Cross Protective Immunity , 2011, PloS one.

[147]  C. Cerini,et al.  Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. , 1987, Journal of immunology.